CooperCompanies stock reports Q3 revenue growth of 1 percent

Published on 09/30/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CooperCompanies stock delivered adjusted EPS of USD 1.15 for fiscal Q3, up 4 percent year over year. Free cash flow reached USD 273.0 million, up 66 percent.

Reinraum-Produktionsanlage für medizinische Geräte mit Technikern an Kontaktlinsen-Fertigungslinien — CooperCompanies Reinraum-Produktion US21664P1039 zeigt automatisierte Kontaktlinsen-Fertigungslinien mit optischer Qualitätsprüfung im sterilen Reinraumbereich, Illustration mit AI erstellt.

CooperCompanies stock reported fiscal third-quarter revenue of USD 1.066 billion for the period ended July 31, 2026, up 1 percent year over year. The result came with non-GAAP diluted EPS of USD 1.15, a 4 percent increase from the prior-year quarter.

Revenue growth stays limited

According to CooperCompanies on September 9, 2026, CooperVision generated USD 717.0 million of revenue in fiscal Q3, unchanged from the prior year, while CooperSurgical revenue rose 2 percent to USD 349.2 million.

The segment split explains the uneven operating picture. CooperSurgical fertility revenue increased 3 percent organically to USD 141.2 million, while CooperVision faced weaker demand in parts of the Americas and Asia Pacific.

Cash flow supports capital returns

Free cash flow rose 66 percent year over year to USD 273.0 million in fiscal Q3, according to the company release. Cash provided by operations reached USD 341.7 million, against capital expenditures of USD 68.7 million.

CooperCompanies said on September 9, 2026, that it would retain CooperSurgical and expand its share repurchase authorization from USD 2.0 billion to USD 3.0 billion. The company had repurchased USD 445.0 million of shares during fiscal 2026 at that point.

Guidance sets the next test

Management guided to fiscal 2026 revenue of USD 4.229 billion to USD 4.252 billion and non-GAAP diluted EPS of USD 4.51 to USD 4.55. The fourth-quarter outlook calls for revenue of USD 1.057 billion to USD 1.080 billion and non-GAAP diluted EPS of USD 1.05 to USD 1.09.

MarketBeat reported on September 26, 2026, that 19 brokerages had a consensus Hold rating, with an average 12-month price target of USD 71.47. The same report cited quarterly adjusted EPS of USD 1.15 against USD 1.12 consensus, a USD 0.03 beat, while quarterly revenue of USD 1.07 billion trailed the USD 1.10 billion estimate.

Market value and operating scale

CooperCompanies had a market capitalization of USD 11.0 billion as of September 30, 2026. The medical device company operates through CooperVision and CooperSurgical, employs 15,000 people and sells products in more than 130 countries.